Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: Analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer

Journal of Nuclear Medicine

Volumn 53, Issue 11, 2012, Pages 1670-1675

  Saylor, Philip J ^a   Mahmood, Umar ^a   Kunawudhi, Anchisa ^a   Smith, Matthew R ^a   Palmer, Edwin L ^a   Michaelson, M Dror ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone metastases; Bone scan; Prostate cancer; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; SUNITINIB;

ADVANCED CANCER; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DRUG RESPONSE; ENZYME INHIBITION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

BONE AND BONES; BONE NEOPLASMS; HUMANS; INDOLES; MALE; MOLECULAR TARGETED THERAPY; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84868316252     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105007     Document Type: Article

References (28)

1. Einhorn TA, Vigorita VJ, Aaron A. Localization of technetium-99m methylene diphosphonate in bone using microautoradiography. J Orthop Res. 1986;4:180-187.
2. Tilden RL, Jackson J Jr, Enneking WF, DeLand FH, McVey JT. 99m Tcpolyphosphate: histological localization in human femurs by autoradiography. J Nucl Med. 1973;14:576-578.
3. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006;12:3361-3367.
4. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88:2919-2926.
5. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
6. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract]. J Clin Oncol. 2011;29(suppl). Available at: http://meeting.ascopubs.org/.
7. Michaelson MD, Oudard S, Ou Y, et al. Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol. 2011;29(suppl). Available at: http://meeting.ascopubs.org/.
8. Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol. 2009;20:913-920.
9. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
11. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
12. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl JMed. 2004;351:1502-1512.
13. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
14. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract]. J Clin Oncol. 2012;30. Available at: http://meeting.ascopubs.org/.
15. Scher H, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study [abstract]. J Clin Oncol. 2012;30. Available at: http://meeting.ascopubs.org/.
16. Pezaro C, Rosenthal MA, Gurney H, et al. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol. 2009;32:338-341.
17. Boccardo F, Rubagotti A, Conti G, et al. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Oncology. 2008;74:223-228.
18. Small EJ, Fontana J, Tannir N, et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007;100:765-769.
19. Gravis G, Bladou F, Salem N, et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol. 2008;19:1624-1628.
20. Yu EY, Massard C, Gross ME, et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011;77:1166-1171.
21. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009;15:7421-7428.
22. Lara PN Jr, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009;20:179-184.
23. Stadler WM, Cao D, Vogelzang NJ, et al. A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004;10:3365-3370.
24. Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007;25:445-451.
25. Bajaj GK, Zhang Z, Garrett-Mayer E, et al. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 2007;69:526-531.
26. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebocontrolled phase iii trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534-1540.
27. Molife LR, Fong PC, Paccagnella L, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer. 2010;103:332-339.
28. Agus DB, Sweeney CJ, Morris MJ, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007;25:675-681.